Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases

被引:53
作者
Völkel, D
Zimmermann, K
Zerr, I
Bodemer, M
Lindner, T
Turecek, PL
Poser, S
Schwarz, HP
机构
[1] Baxter Hyland Immuno, A-1221 Vienna, Austria
[2] Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany
关键词
D O I
10.1046/j.1537-2995.2001.41040441.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Creutzfeldt-Jakob disease is thought to be caused by conversion of cellular prion protein (PrP) from its soluble form (PrPsen) to a pathologic form (PrPres). The occurrence of a new variant of CJD has increased the demand for a rapid assay capable of detecting a theoretical risk of transmission of the disease by blood or plasma. STUDY DESIGN AND METHODS: A quantitative sandwich ELISA for routine screening was developed for analysis of PrP levels in plasma. The time-resolved dissociation-enhanced fluorescence technology allowed a detection limit in plasma samples of approximately 50 pg/mL. Levels of PrPsen were tested in plasma from 31 patients with CJD, from 11 patients with other neurodegenerative diseases, and from a control group of 200 healthy subjects. RESULTS: The assay recognized both PrPsen and pathologic PrPres, but did not differentiate between the two isoforms. PrPsen levels were higher in plasma from both patient groups than in plasma from the control group: 27 of the 31 (87%) CJD patients and all patients with other neurodegenerative diseases had higher levels than the highest concentration found in the control group. No correlation was found between age and PrP level. No signal could be detected in the CJD samples after protease K digestion, indicating that all detected PrP was protease-sensitive and therefore not pathologic. CONCLUSION: These data suggest that soluble PrPsen in plasma samples might be useful as a surrogate marker for a broad spectrum of neurologic diseases as well as for CJD.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 45 条
[21]   EUROPIUM AS A LABEL IN TIME-RESOLVED IMMUNOFLUOROMETRIC ASSAYS [J].
HEMMILA, I ;
DAKUBU, S ;
MUKKALA, VM ;
SIITARI, H ;
LOVGREN, T .
ANALYTICAL BIOCHEMISTRY, 1984, 137 (02) :335-343
[22]   The same prion strain causes vCJD and BSE [J].
Hill, AF ;
Desbruslais, M ;
Joiner, S ;
Sidle, KCL ;
Gowland, I ;
Collinge, J ;
Doey, LJ ;
Lantos, P .
NATURE, 1997, 389 (6650) :448-450
[23]   Increased expression of phosphatidylinositol-specific phospholipase C resistant prion proteins on the surface of activated platelets [J].
Holada, K ;
Mondoro, TK ;
Muller, J ;
Vostal, JG .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) :276-282
[24]   HIGH-LEVELS OF NERVOUS SYSTEM-SPECIFIC PROTEINS IN CEREBROSPINAL-FLUID IN PATIENTS WITH EARLY STAGE CREUTZFELDT-JAKOB DISEASE [J].
JIMI, T ;
WAKAYAMA, Y ;
SHIBUYA, S ;
NAKATA, H ;
TOMARU, T ;
TAKAHASHI, Y ;
KOSAKA, K ;
ASANO, T ;
KATO, K .
CLINICA CHIMICA ACTA, 1992, 211 (1-2) :37-46
[25]   MOUSE POLYCLONAL AND MONOCLONAL-ANTIBODY TO SCRAPIE-ASSOCIATED FIBRIL PROTEINS [J].
KASCSAK, RJ ;
RUBENSTEIN, R ;
MERZ, PA ;
TONNADEMASI, M ;
FERSKO, R ;
CARP, RI ;
WISNIEWSKI, HM ;
DIRINGER, H .
JOURNAL OF VIROLOGY, 1987, 61 (12) :3688-3693
[26]  
Keohane C., 1999, Clinical and Experimental Pathology, V47, P125
[27]   Prion (PrPSc)-specific epitope defined by a monoclonal antibody [J].
Korth, C ;
Stierli, B ;
Streit, P ;
Moser, M ;
Schaller, O ;
Fischer, R ;
SchulzSchaeffer, W ;
Kretzschmar, H ;
Raeber, A ;
Braun, U ;
Ehrensperger, F ;
Hornemann, S ;
Glockshuber, R ;
Riek, R ;
Billeter, M ;
Wuthrich, K ;
Oesch, B .
NATURE, 1997, 390 (6655) :74-77
[28]  
KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1
[29]  
MacGregor I, 1999, VOX SANG, V77, P88
[30]   ULTRASTRUCTURAL ALTERATIONS OF THE VESTIBULAR NUCLEI IN JACOB-CREUTZFELD DISEASE [J].
MANOLIDIS, LS ;
BALOJANNIS, SJ .
ACTA OTO-LARYNGOLOGICA, 1983, 95 (5-6) :508-521